Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLoh, Zoe-
dc.contributor.authorSalvaris, Ross-
dc.contributor.authorChong, Geoffrey-
dc.contributor.authorChurilov, Leonid-
dc.contributor.authorManos, Kate-
dc.contributor.authorBarraclough, Allison-
dc.contributor.authorHawkes, Eliza A-
dc.identifier.citationBritish Journal of Haematology 2021; 193(4): 741-749en
dc.description.abstractEligibility criteria for randomised control trials (RCT) in diffuse large B-cell lymphoma (DLBCL) may be becoming increasingly strict. In this analysis, 42 first-line phase III RCTs enrolling DLBCL patients since 1990 were identified from PubMed and Changes in 31 individual eligibility criteria were assessed using three pre-defined eras [(1) 1993-2005; (2) 2006-2013; and (3) 2014-2020]. The presence of 15/31 criteria increased significantly over time, and the total number of criteria per study also increased over time [median Era 1: 14·5, interquartile range (IQR) 12·6-16·4; Era 2: 21, 18·8-23·3; Era 3: 23, 21-25; P < 0·001]. When each trial's eligibility criteria were applied to 215 consecutive patients from an institutional database treated between 2010 and 2020, a median of 57% (IQR 47-70) of patients were hypothetically eligible for trial enrolment. The median percentage of patients eligible was 68% (56-91), 54% (37-81) and 47% (38-82) for Era 1, 2 and 3 respectively (P = 0·004). Phase III front-line DLBCL trial criteria have become increasingly restrictive over the last three decades, resulting in a diminishing proportion of trial-eligible patients, with less than 50% of our patients eligible for modern-era studies. This potentially impacts generalisability of recent trial results and will likely limit recruitment to ongoing studies.en
dc.subjectdiffuse large B-cell lymphomaen
dc.subjecteligibility criteriaen
dc.subjectrandomised controlled trialsen
dc.titleEvolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.en
dc.typeJournal Articleen
dc.identifier.journaltitleBritish Journal of Haematologyen
dc.identifier.affiliationMelbourne Medical School, University of Melbourne, Melbourne, Vic., Australiaen
dc.identifier.affiliationDepartment of Haematology, Monash Health, Clayton, Vic., Australiaen
dc.identifier.affiliationDepartment of Haematology, Eastern Health, Melbourne, Vic., Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.pubmedid33851428-, Allison
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Wellness and Research Centre- (University of Melbourne)- Florey Institute of Neuroscience and Mental Health- Haematology- Newton-John Cancer Research Institute- Haematology- Newton-John Cancer Wellness and Research Centre- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.